MUC1 and non-small cell lung carcinoma: Although the exact role of blood MUC1 in development and progression of NSCLC has not been completely illuminated, these findings suggest that MUC1 can influence EGFR signaling directly by binding with EGFR or indirectly through it interaction with PI3K-Art pathway, regulating the clinical efficacy of EGFR-TKI treatment.